Table 4 Included studies comparing parenteral oestrogen given at different doses

From: Parenteral oestrogen in the treatment of prostate cancer: a systematic review

Study

N

Comparator

Follow-up

All-cause mortality

Prostate cancer mortality

Cardiovascular adverse events

Study quality

PEP at 320 mg monthly

 Henriksson et al (1988)

38

PEP i.m.

Mean: 14.1 months

NR

NR

0 in all groups

Non-randomised trial

  

(1) 240 mg month−1

     
  

(2) 160 mg month−1

     

 Stege et al (1988)

27

PEP i.m.

6 months

NR

NR

0 in all groups

Insufficient information to assess

  

(1) 240 mg month−1

     
  

(2) 160 mg month−1

     

PEP at 320 mg monthly for 6 months reducing to 160 mg monthly for 6 months

 Stege et al (1989)

17

PEP i.m. 320 mg month−1 for 6 months then 80 mg month−1 for 6 months

NR

NR

NR

0 in both arms

Insufficient information to assess

  1. N=number of patients; NR=not reported; PEP=polyoestradiol phosphate.
  2. Studies are ordered by sample size within dosage categories.
Back to article page